测定口服泊沙康唑 12 或 24 周 4 种方案治疗甲真菌病成人患者的趾甲中泊沙康唑浓度。
Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks.
机构信息
Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4424-6. doi: 10.1128/AAC.01302-10. Epub 2011 Jul 11.
Abstract
Pharmacokinetic data from a randomized, parallel-group, multicenter study are presented. Adults with toenail onychomycosis (n = 146) received posaconazole (100 mg, 200 mg, or 400 mg) once daily (QD) for 24 weeks or 400 mg QD for 12 weeks. The posaconazole concentration in the great toenail exhibited a dose-related increase starting at week 2 for 24 weeks and a mean toenail-to-plasma concentration ratio of approximately 3:1 at the end of treatment for the 400-mg 24-week dose.
摘要
现将一项随机、平行分组、多中心研究的药代动力学数据呈现如下。患有趾甲甲真菌病的成年人（n = 146）接受泊沙康唑（100 mg、200 mg 或 400 mg）每日一次（QD）治疗 24 周或 400 mg QD 治疗 12 周。24 周时，大脚趾甲中的泊沙康唑浓度开始呈剂量相关性增加，400 mg 24 周剂量治疗结束时的平均趾甲-血浆浓度比约为 3:1。
相似文献
1
Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks.测定口服泊沙康唑 12 或 24 周 4 种方案治疗甲真菌病成人患者的趾甲中泊沙康唑浓度。
Antimicrob Agents Chemother. 2011 Sep;55(9):4424-6. doi: 10.1128/AAC.01302-10. Epub 2011 Jul 11.
2
A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.一项多中心、随机、安慰剂和阳性对照、平行分组、研究者设盲的研究，评估了泊沙康唑四种治疗方案用于治疗成人趾甲甲真菌病的疗效。
Br J Dermatol. 2012 Feb;166(2):389-98. doi: 10.1111/j.1365-2133.2011.10660.x. Epub 2011 Dec 6.
3
A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.一项I/II期随机、双盲、安慰剂对照、剂量范围研究，评估拉夫康唑治疗甲癣的疗效、安全性和药代动力学。
J Eur Acad Dermatol Venereol. 2005 Jul;19(4):437-43. doi: 10.1111/j.1468-3083.2005.01212.x.
4
Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole.用艾氟康唑治疗甲癣患者的长期随访
J Drugs Dermatol. 2017 Dec 1;16(12):1269-1273.
5
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole.甲癣的抗真菌脉冲疗法。伊曲康唑1周脉冲疗法每月周期的药代动力学和药效学研究。
Arch Dermatol. 1996 Jan;132(1):34-41. doi: 10.1001/archderm.132.1.34.
6
Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis.10%依氟康唑局部溶液：治疗趾甲甲真菌病的配方和疗效评估。
Mycoses. 2020 May;63(5):517-524. doi: 10.1111/myc.13062. Epub 2020 Mar 6.
7
Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.三剂每周一次氟康唑（150、300和450毫克）治疗趾甲远端甲下甲真菌病的药代动力学
J Am Acad Dermatol. 1998 Jun;38(6 Pt 2):S103-9. doi: 10.1016/s0190-9622(98)70493-1.
8
9
Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients.10%艾氟康唑溶液用于治疗拉丁裔患者的趾甲甲癣。
Cutis. 2017 Apr;99(4):286-289.
10
Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study.艾氟康唑溶液治疗趾甲甲真菌病：一项2期多中心随机双盲研究。
J Drugs Dermatol. 2013 Feb;12(2):186-92.
引用本文的文献
1
Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.基于脂质的纳米制剂在甲癣治疗中的应用：应对当前治疗的挑战并推进治疗进展
RSC Adv. 2025 Mar 11;15(10):7799-7825. doi: 10.1039/d5ra00387c. eCollection 2025 Mar 6.
2
Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review.影响泊沙康唑血药浓度的因素：一项荟萃分析与系统评价
Front Pharmacol. 2024 Dec 19;15:1450120. doi: 10.3389/fphar.2024.1450120. eCollection 2024.
3
Pharmacokinetics and Pharmacodynamics of Posaconazole.泊沙康唑的药代动力学和药效学。
Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y.
4
Tissue penetration of antifungal agents.抗真菌药物的组织穿透性。
Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13.
本文引用的文献
1
Skin concentrations and pharmacokinetics of posaconazole after oral administration.口服泊沙康唑后的皮肤浓度和药代动力学。
Antimicrob Agents Chemother. 2010 May;54(5):1807-10. doi: 10.1128/AAC.01616-09. Epub 2010 Mar 1.
2
A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma.一种用于测定人血浆中泊沙康唑的灵敏液相色谱-质谱联用方法。
J Pharm Biomed Anal. 2007 Jan 4;43(1):228-36. doi: 10.1016/j.jpba.2006.06.011. Epub 2006 Jul 21.
3
In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.泊沙康唑、雷夫康唑、特比萘芬、伊曲康唑和氟康唑对皮肤癣菌、酵母菌及非皮肤癣菌属的体外活性。
Med Mycol. 2005 Mar;43(2):179-85. doi: 10.1080/13693780410001731583.
4
Pharmacokinetics of antifungal agents in onychomycoses.抗真菌药物在甲癣中的药代动力学。
Clin Pharmacokinet. 2001;40(6):441-72. doi: 10.2165/00003088-200140060-00005.
5
Determination of terbinafine in nail samples during systemic treatment for onychomycoses.
Br J Dermatol. 1990 Oct;123(4):481-6. doi: 10.1111/j.1365-2133.1990.tb01453.x.
6
Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis.伊曲康唑通过甲母质和甲床渗透入指甲——一项关于甲癣的研究。
Clin Exp Dermatol. 1991 Sep;16(5):374-6. doi: 10.1111/j.1365-2230.1991.tb00405.x.
7
Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis.
J Am Acad Dermatol. 1992 May;26(5 Pt 1):731-5. doi: 10.1016/0190-9622(92)70102-l.
Zotero 插件